Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Dupilumab for COPD
Recruiting1 awardPhase 3
San Diego, California
This trial is testing the efficacy of a new drug, dupilumab, for treating moderate or severe COPD. The primary objective is to measure the annualized rate of acute COPD exacerbation (AECOPD) and the secondary objectives are to assess the effects of the drug on lung function and health-related quality of life. The trial will also evaluate the safety and tolerability of the drug and the incidence of antidrug antibodies (ADA).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service